يعرض 721 - 740 نتائج من 19,650 نتيجة بحث عن '(( significantly increased decrease ) OR ( significant ((non decrease) OR (a decrease)) ))*', وقت الاستعلام: 0.61s تنقيح النتائج
  1. 721
  2. 722
  3. 723
  4. 724

    The strength of the commute time-functional connectivity relationship demonstrates weak pathological significance and weak dependency on age. حسب Rostam M. Razban (22232522)

    منشور في 2025
    "…The corresponding Kolmogorov-Smirnov pairwise tests are not significant (S5 Table in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0331085#pone.0331085.s001" target="_blank">SI</a>). …"
  5. 725

    5-HT inhibits <i>P</i>. <i>berghei</i> infection in mosquitoes. حسب Li Gao (131516)

    منشور في 2024
    "…(B and D) The abundance of each metabolite was normalized to the mean value of the healthy groups and shown as log2. Significantly altered metabolites (B-H FDR < 0.1, log<sub>2</sub>(FC) > 1) are highlighted in blue (decreased) and red (increased), respectively. …"
  6. 726

    DDC for four anticoagulants from 2019 to 2023. حسب Wei Luo (80175)

    منشور في 2025
    الموضوعات:
  7. 727
  8. 728
  9. 729

    Utilization of anticoagulants from 2019 to 2023. حسب Wei Luo (80175)

    منشور في 2025
    الموضوعات:
  10. 730
  11. 731
  12. 732
  13. 733
  14. 734

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  15. 735

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  16. 736

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  17. 737
  18. 738
  19. 739
  20. 740